Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/0284186X.2022.2117571 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Longitudinal circulating tumor DNA monitoring in predicting response to short-course radiotherapy followed by neoadjuvant chemotherapy and camrelizumab in locally advanced rectal cancer: data from a Phase Ⅲ clinical trial (UNION).
Cancer Lett
January 2025
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China; Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China; Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, 430022, China. Electronic address:
This study, conducted as part of a multicenter phase III clinical trial, aimed to assess the utility of circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) in comparing the efficacy of short-course and long-course chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC). A total of 244 plasma samples from 79 LARC patients undergoing neoadjuvant therapy (NAT) before surgery were collected at various time points. Targeted deep sequencing using a novel MRD panel was performed.
View Article and Find Full Text PDFTreatment Pattern and Outcome of Locally Advanced Rectal Cancer in Resource-Constrained Countries: Experience at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.
JCO Glob Oncol
January 2025
Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN.
Purpose: Management of locally advanced rectal cancer (LARC) includes neoadjuvant chemoradiotherapy (NACRT) followed by total mesorectal excision. Recently, total neoadjuvant treatment (TNT) has gained attention. In developing countries, patients with rectal cancer often present at advanced stages.
View Article and Find Full Text PDFClinical and functional outcomes of utilising nail cement spacer as a frugal method of reconstruction for tumours of the proximal humerus.
J Clin Orthop Trauma
January 2025
Department of Orthopaedics, Rehman Medical Institute, 5/B-2, Phase 5 Hayatabad, Peshawar, Pakistan.
Background: The shoulder girdle and proximal humerus are common sites for neoplastic lesions be it benign or malignant. We aimed to evaluate the outcomes of a frugal method of reconstruction of the proximal humerus for neoplastic lesions at short to medium term follow-up.
Methods: Data for this retrospective case series was collected from an electronic data base held at the primary authors institution.
Nutritional status and associated factors among adult tuberculosis patients in public health centres of Horro Guduru Wollega Zone, Oromia Region, Western Ethiopia.
J Nutr Sci
December 2024
Department of Nutrition and Dietetics, Faculty of Public Health, Institute of Health, Jimma University, Jimma, Ethiopia.
Article Synopsis
- The study focused on assessing nutritional status among adult tuberculosis (TB) patients in public health centres in Western Ethiopia during 2021.
- Data was gathered from 334 TB patients using questionnaires and measurements, revealing a high prevalence of undernutrition (48.2%) and some overnutrition (8.7%).
- Key factors linked to undernutrition included being female, not receiving dietary counselling, being in the initiation phase of TB treatment, and eating less than three meals a day, highlighting the need for improved nutritional support and counselling for these patients.
Short-Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.
Cancer Med
December 2024
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Backgroud: The high cost of blinatumomab in full doses of full treatments has led to dose reduction and fewer treatment cycles for most patients in China. With current needs for cost-efficiency and resource management in health care, we retrospectively evaluated the clinical effects of short-course blinatumomab treatment for R/R Ph- B-ALL at our center.
Methods: Blinatumomab was administered with 24-h continuous intravenous infusion (9 μg/day for the first 3 days and 28 μg/day for 6-10 days).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!